Hordowicz Martyna, Jarosz Jerzy, Czaplińska Małgorzata, Leonhard Agnieszka, Klimkiewicz Anna
Hospice of St. Christopher in Warsaw, 02-781 Warsaw, Poland.
Polish Society of Medical Cannabis and Cannabinoids, 02-781 Warsaw, Poland.
J Clin Med. 2021 Sep 30;10(19):4545. doi: 10.3390/jcm10194545.
(1) Background: In November 2017, medical cannabis was legalized in Poland. Until now, there have been no studies conducted to examine the perspectives of Polish physicians about their preferences regarding medical cannabis legal status and educational needs. (2) Methods: The survey was a self-developed online questionnaire with 57 participants. Participation was voluntary. The link was shared through a personal network of medical doctors, regional medical chambers, and with doctors attending palliative care courses organized by our research group. Results: Between June and October 2020, 173 HCPs from Poland completed the survey. More than half of the study participants never received any education on medical cannabis (60.1%); 71.1% declared their knowledge was insufficient to counsel patients about medical cannabis use. The majority claimed that they would like to be able to answer patient questions (92.4%); 93.1% declared a need to create clear guidelines for using cannabinoids in clinical practice. Furthermore, 71.7% believed that medicines containing cannabinoids and 52.0% that herbal cannabis should be reimbursed (3). Conclusion: Most medical doctors do not feel prepared for patient counseling. They could benefit from targeted educational interventions. We have also identified physicians' preferences that might inspire the stakeholders involved who are critical for shaping policies regarding cannabis-based therapeutics.
(1) 背景:2017年11月,医用大麻在波兰合法化。迄今为止,尚未开展研究以调查波兰医生对医用大麻法律地位的偏好及教育需求的看法。(2) 方法:该调查采用自行设计的在线问卷,有57名参与者。参与是自愿的。链接通过医生个人网络、地区医学会以及参加我们研究小组组织的姑息治疗课程的医生进行分享。结果:2020年6月至10月期间,来自波兰的173名医疗保健专业人员完成了调查。超过一半的研究参与者从未接受过任何关于医用大麻的教育(60.1%);71.1%表示他们的知识不足以就医用大麻的使用为患者提供咨询。大多数人声称他们希望能够回答患者的问题(92.4%);93.1%表示需要制定临床实践中使用大麻素的明确指南。此外,71.7%的人认为含大麻素的药物以及52.0%的人认为草药大麻应予以报销。(3) 结论:大多数医生觉得没有为患者咨询做好准备。他们可以从有针对性的教育干预中受益。我们还确定了医生的偏好,这可能会激励参与制定基于大麻的治疗政策的关键利益相关者。